Log-rank progression-free survival (PFS) analysis was performed by using cutoff values of the top 1⁄2 density of tumor-infiltrating immune cells, such as CD8+ T cells (CD8+ T-high defined as patients with the top 1⁄2 CD8+ T cell density in the tumor; others defined as CD8+ T-low), M1/M2 macrophages and CD56bright, CD56dim NK cells, in NSCLC tissues (Figures 5A–H). This evidence concerns the gene CD8A and non-small cell lung carcinoma.